Moody's Investors Service affirmed its "A1" rating on Boston-based Dana-Farber Cancer Institute.
The rating affirmation is a result of several factors, including the institute's prominence in cancer research, strong fundraising capabilities, improved operating performance and long-standing relationships with other leading academic medical centers.
The outlook is stable.